In this context, treatment with retinoic acid and arsenic, two agents that induce disease-remission in APL patients, leads to PML-RARA degradation, cell differentiation, re-assembly of PML-NBs, and tumor regression. The gene discussed is PML; the disease is acute promyelocytic leukemia.